Loading
The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Fever, cough or breathlessness, rapid weight gain or swelling, bone pain, low blood pressure or reduced urine; the labels say to start steroids and monitor at the first suspicion, and the syndrome has been fatal.
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
Blisters, peeling, or sores in the mouth or eyes with a rash. Enfortumab vedotin carries a boxed warning for Stevens-Johnson syndrome and toxic epidermal necrolysis, mostly in the first cycle.
Nausea, vomiting, muscle cramps, palpitations, seizures, confusion or passing much less urine in the first days of a new dose; the label requires hydration, anti-hyperuricaemic drugs and blood tests around each ramp-up step.
QT: both Ivosidenib and Gilteritinib prolong the QT interval (known and known risk).. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
See all on the product pages:AzacitidineCPX-351 (liposomal daunorubicin-cytarabine)Cytarabine + anthracycline ('7+3')Decitabine + cedazuridine (oral)EnasidenibGemtuzumab ozogamicinGilteritinibIvosidenibMidostaurinOlutasidenibQuizartinibRevumenibVenetoclaxZiftomenib·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Acute myeloid leukaemia, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.